MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA-BASED VACCINE CANDIDATE IN HEALTHY CHILDREN
Clinical Trial Grant
Awarded By
Pfizer, Inc.
Start Date
September 26, 2022
End Date
September 20, 2024
Awarded By
Pfizer, Inc.
Start Date
September 26, 2022
End Date
September 20, 2024